Quanterix (QTRX)


Market Price (11/16/2026): $2.94 | Market Cap: $139.6 MilSector: Health Care | Industry: Life Sciences Tools & Services

Quanterix (QTRX)


Market Price (11/16/2026): $2.94
Market Cap: $139.6 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -29%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more.

Weak multi-year price returns
2Y Excs Rtn is -108%, 3Y Excs Rtn is -161%

Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.74

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -90 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -61%

Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -13%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -38%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -38%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -85%

Key risks
QTRX key risks include [1] a planned financial restatement caused by material weaknesses in internal controls, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -29%
2 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -108%, 3Y Excs Rtn is -161%
4 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.74
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -90 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -61%
6 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -13%
7 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11%
8 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -38%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -38%
9 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -85%
10 Key risks
QTRX key risks include [1] a planned financial restatement caused by material weaknesses in internal controls, Show more.

QTRX in ETFs

Weight = QTRX's share of each fund

VTI0.00%
IWM0.00%
IWN0.01%
IBB0.01%
VTWO0.01%
VHT0.00%
IWV0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/13/2026

Nov 12: down 5.3% in one day (S&P 500 down 0.4%)
The stock declined without company news. The broader market also moved lower that day.

Down 28.6% from its Oct 5 high to Oct 20, up 7.7% since (S&P 500 down 0.7%)
The stock declined throughout this period without company news. The market's broader sell-off in tech and software contributed to the drop on Oct 16, while Oct 6 also saw a notable decline.

Nov 9: up 16.8% on its earnings report (S&P 500 up 2.4%)
The stock rose following the Q3 2026 earnings release, reporting $35M revenue and improved net income and diluted EPS year-over-year. The broader market also rose significantly that day, staging a broad-based relief rally.

Show more
Prices as of 11/13/2026

Nov 12: down 5.3% in one day (S&P 500 down 0.4%)
The stock declined without company news. The broader market also moved lower that day.

Down 28.6% from its Oct 5 high to Oct 20, up 7.7% since (S&P 500 down 0.7%)
The stock declined throughout this period without company news. The market's broader sell-off in tech and software contributed to the drop on Oct 16, while Oct 6 also saw a notable decline.

Nov 9: up 16.8% on its earnings report (S&P 500 up 2.4%)
The stock rose following the Q3 2026 earnings release, reporting $35M revenue and improved net income and diluted EPS year-over-year. The broader market also rose significantly that day, staging a broad-based relief rally.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -15.8% change in QTRX stock from 7/31/2026 to 11/15/2026 was primarily driven by a -16.9% change in the company's P/S Multiple.
(LTM values as of)731202611152026Change
Stock Price ($)3.482.93-15.8%
Change Contribution By: 
Total Revenues ($ Mil)1451482.2%
P/S Multiple1.10.9-16.9%
Shares Outstanding (Mil)4747-0.9%
Cumulative Contribution-15.8%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/15/2026
ReturnCorrelation
QTRX-15.8% 
Market (SPY)1.2%26.2%
Sector (XLV)16.6%5.0%

Fundamental Drivers

The -6.4% change in QTRX stock from 4/30/2026 to 11/15/2026 was primarily driven by a -11.2% change in the company's P/S Multiple.
(LTM values as of)430202611152026Change
Stock Price ($)3.132.93-6.4%
Change Contribution By: 
Total Revenues ($ Mil)1391486.7%
P/S Multiple1.10.9-11.2%
Shares Outstanding (Mil)4747-1.2%
Cumulative Contribution-6.4%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/15/2026
ReturnCorrelation
QTRX-6.4% 
Market (SPY)5.5%28.4%
Sector (XLV)30.4%5.9%

Fundamental Drivers

The -45.1% change in QTRX stock from 10/31/2025 to 11/15/2026 was primarily driven by a -43.8% change in the company's P/S Multiple.
(LTM values as of)1031202511152026Change
Stock Price ($)5.342.93-45.1%
Change Contribution By: 
Total Revenues ($ Mil)12414819.0%
P/S Multiple1.70.9-43.8%
Shares Outstanding (Mil)3947-17.9%
Cumulative Contribution-45.1%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/15/2026
ReturnCorrelation
QTRX-45.1% 
Market (SPY)11.8%30.3%
Sector (XLV)33.1%13.0%

Fundamental Drivers

The -86.5% change in QTRX stock from 10/31/2023 to 11/15/2026 was primarily driven by a -87.2% change in the company's P/S Multiple.
(LTM values as of)1031202311152026Change
Stock Price ($)21.722.93-86.5%
Change Contribution By: 
Total Revenues ($ Mil)11114833.4%
P/S Multiple7.30.9-87.2%
Shares Outstanding (Mil)3747-20.9%
Cumulative Contribution-86.5%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/15/2026
ReturnCorrelation
QTRX-86.5% 
Market (SPY)87.0%36.2%
Sector (XLV)59.4%30.0%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
QTRX Return-9%-67%97%-61%-40%-54%-94%
Peers Return21%-49%22%-20%-5%56%-11%
S&P 500 Return27%-19%24%23%16%11%103%

Monthly Win Rates [3]
QTRX Win Rate50%42%83%25%25%36% 
Peers Win Rate60%33%57%38%53%62% 
S&P 500 Win Rate75%42%67%75%67%45% 

Max Drawdowns [4]
QTRX Max Drawdown-59%-82%-32%-65%-65%-70% 
Peers Max Drawdown-26%-57%-42%-39%-46%-40% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: LAB, BIO, TECH, TXG, TMO. See QTRX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/13/2026 (YTD)

How Low Can It Go

EventQTRXS&P 500
2025 US Tariff Shock
  % Loss-45.2%-18.8%
  % Gain to Breakeven82.5%23.1%
  Time to Breakeven240 days79 days
2024 Yen Carry Trade Unwind
  % Loss-17.8%-7.8%
  % Gain to Breakeven21.6%8.5%
  Time to Breakeven10 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-16.1%-9.5%
  % Gain to Breakeven19.2%10.5%
  Time to Breakeven32 days24 days
2023 SVB Regional Banking Crisis
  % Loss-25.5%-6.7%
  % Gain to Breakeven34.2%7.1%
  Time to Breakeven16 days31 days
2020 COVID-19 Crash
  % Loss-61.1%-33.7%
  % Gain to Breakeven157.1%50.9%
  Time to Breakeven121 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-19.1%-19.2%
  % Gain to Breakeven23.7%23.8%
  Time to Breakeven57 days105 days

Compare to LAB, BIO, TECH, TXG, TMO

In The Past

Quanterix's stock fell -45.2% during the 2025 US Tariff Shock. Such a loss loss requires a 82.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventQTRXS&P 500
2025 US Tariff Shock
  % Loss-45.2%-18.8%
  % Gain to Breakeven82.5%23.1%
  Time to Breakeven240 days79 days
2023 SVB Regional Banking Crisis
  % Loss-25.5%-6.7%
  % Gain to Breakeven34.2%7.1%
  Time to Breakeven16 days31 days
2020 COVID-19 Crash
  % Loss-61.1%-33.7%
  % Gain to Breakeven157.1%50.9%
  Time to Breakeven121 days140 days

Compare to LAB, BIO, TECH, TXG, TMO

In The Past

Quanterix's stock fell -45.2% during the 2025 US Tariff Shock. Such a loss loss requires a 82.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Quanterix (QTRX)

```html

Quanterix Corporation (QTRX) is a life sciences company that develops and markets advanced digital immunoassay platforms designed to enhance precision health. The company's core mission is to provide tools that significantly improve the sensitivity and multiplexing capabilities for detecting proteins and other biomarkers, serving both life sciences research and diagnostics globally across North America, Europe, the Middle East, Africa, and the Asia Pacific regions.

The company's main product offerings include a suite of sophisticated instruments based on its proprietary Simoa (Single Molecule Array) detection technology. These instruments, such as the HD-X, SR-X, and SP-X, enable highly sensitive and often multiplexed detection of proteins and even direct detection of nucleic acids for a wide range of applications. Complementing its instruments, Quanterix also supplies essential consumables like assay kits and reagents. Furthermore, the company provides contract research services, offering expertise in sample testing, custom assay development, and homebrew assay development to its clients.

Quanterix primarily targets the life science research sector, with its customer base comprising laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies. Their technology is critical in several key therapeutic areas, including neurology, oncology, cardiology, infectious diseases, and inflammation, facilitating deeper scientific understanding and aiding in the development of new diagnostic and therapeutic solutions.

```

AI Analysis | Feedback

Here are 1-3 brief analogies to describe Quanterix:

  • They're like Illumina, but for ultra-sensitive protein detection and biomarker analysis instead of DNA sequencing.
  • Imagine a specialized Thermo Fisher Scientific that focuses entirely on developing ultra-sensitive instruments and assays to detect minute amounts of disease-related biomarkers.

AI Analysis | Feedback

```html
  • HD-X Instrument: A sensitive, automated platform for multiplex protein detection.
  • SR-X Instrument: An instrument that applies Simoa detection technology for various applications, including direct nucleic acid detection.
  • SP-X Instrument: A platform based on Simoa planar array technology for measuring multiplex chemiluminescent immunoassays.
  • Assay Kits & Consumables: Complementary kits, reagents, and other consumables essential for use with their immunoassay platforms.
  • Contract Research Services: Services encompassing sample testing, homebrew assay development, and custom development to support life sciences research.
```

AI Analysis | Feedback

Major Customers of Quanterix (QTRX)

Based on the provided description, Quanterix sells its products and services primarily to organizations within the life science research sector. While specific customer names are not listed in the background information, its major customer categories include:

  • Academic and Governmental Research Institutions: This category encompasses laboratories associated with universities, colleges, and various governmental research agencies.
  • Pharmaceutical and Biotechnology Companies: These are companies involved in the research, development, and manufacturing of drugs and biological products.
  • Contract Research Organizations (CROs): These companies provide research services on a contract basis to the pharmaceutical, biotechnology, and medical device industries.

AI Analysis | Feedback

null

AI Analysis | Feedback

Here is the management team of Quanterix (QTRX):

Everett Cunningham, President and Chief Executive Officer

Everett Cunningham was appointed President and Chief Executive Officer of Quanterix, effective January 19, 2026. Prior to joining Quanterix, he served as Chief Commercial Officer at Illumina since June 2024, where he was responsible for the company's global commercial strategy and execution. During his tenure at Illumina, he helped implement a redesigned commercial operating model. Before Illumina, Mr. Cunningham was Chief Commercial Officer at Exact Sciences, where he led marketing, sales, and customer service for their cancer screening and precision oncology diagnostics portfolio. He also held senior leadership positions at Quest Diagnostics, GE Healthcare, and Pfizer.

Vandana Sriram, Chief Financial Officer

Vandana Sriram is the Chief Financial Officer of Quanterix. Her insider holdings at Quanterix were reported in February 2026.

AI Analysis | Feedback

Here are the key risks to Quanterix's business:

  1. Reliance on Single-Source Contract Manufacturers: Quanterix is significantly exposed to supply chain risk due to its dependence on single-source contract manufacturers, including STRATEC, Paramit, and Columbia Tech, for the production of its critical Simoa HD-X, SR-X, PhenoCycler, and PhenoImager instruments. Any failure, delay, or quantity shortfall from these manufacturers or their own limited suppliers could materially disrupt instrument supply, adversely affecting Quanterix's business, financial condition, operating results, and reputation.
  2. Market Headwinds and Profitability Challenges: The company faces ongoing market headwinds, including reduced funding in academic research and biopharma spending. This has contributed to revised revenue guidance and persistent net losses. While Quanterix aims to achieve cash flow breakeven in the second half of 2026, the path to sustained profitability remains uncertain, with the company recording significant losses in recent periods.
  3. Risk of Technological Obsolescence and Intense Competition: Operating in the rapidly innovating biotechnology sector, Quanterix faces the constant threat that its current Simoa technologies could become obsolete. Competitors may introduce more efficient or cost-effective diagnostic technologies, necessitating continuous investment in research and development to maintain its competitive edge.

AI Analysis | Feedback

null

AI Analysis | Feedback

Quanterix Corporation (QTRX) has significantly expanded its addressable market through strategic acquisitions. Following the acquisition of Akoya Biosciences in 2025, Quanterix's served addressable market expanded from an initial $1 billion to $5 billion. This expanded global market encompasses key therapeutic areas such as neurology, immunology, and oncology, and also extends to inflammation and infectious diseases, leveraging the combined capabilities of their Simoa and Spatial Biology platforms. In addition to its product platforms, Quanterix also offers contract research services. The global contract research organization (CRO) services market, which includes these services, was valued at approximately USD 77.0 billion in 2024. This market is projected to reach USD 162.1 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2033. North America held the largest share of the global CRO market, accounting for 35% in 2024. Oncology applications dominate the CRO services market, representing a 35.4% share in 2024.

AI Analysis | Feedback

Quanterix Corporation (QTRX) is poised for future revenue growth over the next two to three years, driven by its strategic focus on key areas within precision health and life sciences research. The company's anticipated growth drivers include the commercialization of its Alzheimer's diagnostics, sustained expansion in consumables and assay sales, the successful integration of Akoya Biosciences and corresponding market penetration in spatial biology, and the broader adoption of its ultra-sensitive Simoa and spatial biology platforms.

One primary driver is the **advancement and commercialization of Alzheimer's diagnostics**. Quanterix is actively pursuing FDA approval for its Alzheimer's diagnostics, with significant growth targeted for 2027. The company reached key milestones in late 2025 and early 2026, including the Centers for Medicare & Medicaid Services (CMS) approving a reimbursement rate of $897 for its LucentAD Complete test, and the submission of a 510(k) premarket notification to the FDA for the same test in January 2026.

Secondly, **continued growth in consumables and assay sales** is expected to fuel revenue. Consumables demonstrated strong performance in Q4 2025, and Quanterix anticipates this trend to persist. By the end of 2025, recurring revenue, largely from consumables, constituted approximately 75% of the total revenue, indicating a stable and growing base.

A third significant driver is the **strategic integration of Akoya Biosciences and expansion into spatial biology**. The acquisition of Akoya Biosciences expanded Quanterix's portfolio, creating an integrated platform for biomarker analysis across both blood (Simoa) and tissue (spatial biology). The company is on track to realize planned cost synergies from this integration, with the remaining synergies expected to be captured by the end of Q1 2026. This expanded offering allows Quanterix to address new markets and applications.

Lastly, **broadening adoption of Simoa and spatial biology platforms** is critical for future revenue. Quanterix has seen accelerating scientific validation and publication activity, with cumulative publications reaching over 6,300 by year-end 2025, reflecting increasing researcher adoption of both its Simoa and spatial biology technologies. The company is focused on deepening customer and partner relationships, which is expected to drive further utilization and placement of its instruments.

AI Analysis | Feedback

Share Repurchases

  • Quanterix repurchased $1.45 million in common stock in 2025.
  • The company repurchased $2.61 million in common stock in 2024.
  • In 2023, share repurchases amounted to $0.2 million.

Share Issuance

  • In February 2021, Quanterix completed a public offering of 4,107,142 shares of common stock at $70.00 per share, generating approximately $287.5 million in gross proceeds.
  • As part of the Akoya Biosciences acquisition in July 2025, Quanterix offered 7.8 million shares to Akoya's investors.
  • Proceeds from common stock issued under stock plans were $0.74 million in 2025, a decrease from $3.07 million in 2024, and $2.89 million in 2023.

Outbound Investments

  • Quanterix acquired Akoya Biosciences in July 2025, an investment that included 7.8 million shares offered and $20 million paid, aiming to add integrated spatial biology capabilities and diversify revenue streams.
  • In January 2025, Quanterix acquired Emission, Inc. for an upfront payment of $10.0 million, with potential additional payments of $10.0 million upon technical milestones and up to $50.0 million in earnout payments through December 31, 2029.
  • The company has implemented $74 million of an $85 million cost-synergy target related to the Akoya acquisition by the end of 2025, with full realization expected by the first quarter of 2026.

Capital Expenditures

  • Quanterix's capital expenditures were $2.61 million in 2025, $3.37 million in 2024, $3.84 million in 2023, $11.61 million in 2022, and $13.68 million in 2021.
  • Capital expenditures are primarily focused on purchasing equipment to support the company's infrastructure and enhancing product offerings, including the planned launch of the next-generation Simoa ONE instrument by the end of 2025.
  • The company expects to incur additional capital expenditures in future periods to support these efforts and aims to achieve cash flow breakeven in the second half of 2026.

Better Bets vs. Quanterix (QTRX)

Peer Outperformance in Life Sciences Tools & Services

QTRX has trailed 78% of its 108 Life Sciences Tools & Services peers over 5Y. Among the peers that beat it are IQV and DHR. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that QTRX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
30%
of 124 industry peers · -49.0% return
3Y
20%
of 113 industry peers · -86.6% return
5Y
22%
of 108 industry peers · -94.7% return
Life Sciences Tools & Services peers with revenue growth within 4pp of QTRX's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
QTRX Quanterix 8.9% -1.2x -49.0%-86.6%-94.7% —
IQV IQVIA 5.3% 31.3x 20.2%29.5%5.3% +100pp
DHR Danaher 6.9% 37.9x 6.1%13.4%-10.2% +84pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is QTRX's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 6 10.3%56.1%108.0% CAH 517% · MCK 409% · COR 206%
Health Care Services 20 30.9%20.9%12.5% RDNT 145% · HIMS 141% · DGX 95%
Managed Health Care 8 72.3%-2.6%2.7% OSCR 155% · HQY 54% · HUM 8%
Health Care Facilities 26 18.0%25.0%-6.7% THC 257% · NHC 227% · EHC 196%
Health Care Equipment 50 7.8%11.1%-15.2% GKOS 401% · UFPT 346% · TMDX 255%
Pharmaceuticals 60 -15.0%7.7%-39.5% LQDA 1081% · KNSA 639% · XERS 572%
Health Care Supplies 11 26.2%6.1%-39.8% LNTH 241% · HAE 112% · MMSI 27%
Life Sciences Tools & Services ← 109 -15.3%-17.9%-74.4% AXGN 378% · MEDP 199% · NTRA 175%
Biotechnology 365 -26.3%-32.0%-81.4% ELVN 1259% · TRVI 1141% · DNTH 1129%
Health Care Technology 22 -20.8%-57.2%-82.3% VEEV -4% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

QTRXLABBIOTECHTXGTMOMedian
NameQuanterixStandard.Bio-Rad .Bio-Tech.10x Geno.Thermo F. 
Mkt Price2.940.70366.2772.7658.18699.0265.47
Mkt Cap0.10.39.811.47.6258.68.7
Rev LTM148842,5931,22861947,351923
Op Inc LTM-90-47161262-768,86357
FCF LTM-56-66329308947,596201
FCF 3Y Avg-55-104297259677,161163
CFO LTM-56-644683381009,324219
CFO 3Y Avg-53-98457297768,692187

Growth & Margins

QTRXLABBIOTECHTXGTMOMedian
NameQuanterixStandard.Bio-Rad .Bio-Tech.10x Geno.Thermo F. 
Rev Chg LTM14.5%-2.2%1.4%0.9%-3.6%8.3%1.2%
Rev Chg 3Y Avg8.9%-5.6%-1.6%2.4%1.6%3.0%2.0%
Rev Chg Q-13.1%-0.9%0.5%4.6%1.1%9.1%0.8%
QoQ Delta Rev Chg LTM-3.4%-0.2%0.1%1.1%0.3%2.2%0.2%
Op Inc Chg LTM10.4%49.9%-27.9%4.4%46.5%10.1%10.3%
Op Inc Chg 3Y Avg-31.9%1.2%-22.8%-2.5%24.7%6.7%-0.6%
Op Mgn LTM-61.0%-56.0%6.2%21.3%-12.2%18.7%-3.0%
Op Mgn 3Y Avg-58.9%-81.8%8.9%20.5%-21.0%18.2%-6.0%
QoQ Delta Op Mgn LTM3.0%18.1%-2.5%-1.1%2.7%0.4%1.5%
CFO/Rev LTM-37.8%-76.1%18.1%27.5%16.1%19.7%17.1%
CFO/Rev 3Y Avg-38.7%-99.5%17.7%24.7%12.0%19.6%14.9%
FCF/Rev LTM-37.9%-77.8%12.7%25.1%15.2%16.0%13.9%
FCF/Rev 3Y Avg-40.8%-105.8%11.5%21.5%10.6%16.1%11.1%

Valuation

QTRXLABBIOTECHTXGTMOMedian
NameQuanterixStandard.Bio-Rad .Bio-Tech.10x Geno.Thermo F. 
Mkt Cap0.10.39.811.47.6258.68.7
P/S0.93.33.89.312.35.54.6
P/Op Inc-1.5-5.861.043.6-100.729.213.8
P/EBIT-1.5-5.47.248.3-109.727.42.8
P/E-1.32.19.666.3-113.536.65.8
P/CFO-2.5-4.321.033.876.327.724.3
Total Yield-80.1%47.6%10.4%1.9%-0.9%3.0%2.5%
Dividend Yield0.0%0.0%0.0%0.4%0.0%0.3%0.0%
FCF Yield 3Y Avg-22.5%-21.0%3.4%2.4%2.4%3.2%2.4%
D/E0.20.10.10.00.00.20.1
Net D/E-0.3-1.6-0.0-0.0-0.10.1-0.0

Returns

QTRXLABBIOTECHTXGTMOMedian
NameQuanterixStandard.Bio-Rad .Bio-Tech.10x Geno.Thermo F. 
1M Rtn2.4%10.8%3.6%0.4%-16.7%1.3%1.9%
3M Rtn13.5%-2.1%2.8%0.7%3.7%18.9%3.3%
6M Rtn6.9%-29.2%48.0%68.7%174.4%59.8%53.9%
12M Rtn-48.8%-43.8%17.0%23.4%266.1%21.2%19.1%
3Y Rtn-86.6%-68.3%20.3%21.3%45.7%49.4%20.8%
1M Excs Rtn-2.6%7.5%2.0%2.1%-18.0%2.0%2.0%
3M Excs Rtn2.3%3.4%4.7%2.4%2.0%21.1%2.9%
6M Excs Rtn4.1%-32.0%45.1%65.9%171.6%56.9%51.0%
12M Excs Rtn-54.9%-52.0%0.7%8.1%237.4%8.1%4.4%
3Y Excs Rtn-160.8%-136.1%-53.8%-47.7%-20.4%-18.4%-50.7%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Single Segment139137122106 
Collaboration and license revenue    1
Grant revenue    5
Product revenue    81
Service revenue    24
Total139137122106111


Net Income by Segment
$ Mil202520242023
Single Segment-107-39-28
Total-107-39-28


Price Behavior

Price Behavior
Market Price$2.93 
Market Cap ($ Bil)0.1 
First Trading Date12/07/2017 
Distance from 52W High-63.6% 
   50 Days200 Days
DMA Price$3.05$3.67
DMA Trendindeterminatedown
Distance from DMA-3.9%-20.1%
 3M1YR
Volatility83.4%94.4%
Downside Capture160.66291.27
Upside Capture192.97194.08
Correlation (S&P 500)38.8%30.8%
QTRX Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta2.571.711.501.971.961.83
Up Beta11.272.740.980.981.161.80
Down Beta2.313.77-0.552.051.711.67
Up Capture13%131%212%261%290%230%
Bmk +ve Days12182862130427
Stock +ve Days10233357109343
Down Capture339%50%267%211%171%113%
Bmk -ve Days10253664121325
Stock -ve Days12202963134396

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with QTRX
QTRX-44.0%94.4%-0.17-
Sector ETF (XLV)25.8%16.8%1.1813.0%
Equity (SPY)11.6%13.7%0.5430.0%
Gold (GLD)-7.9%28.9%-0.2912.2%
Commodities (DBC)33.8%21.3%1.26-18.2%
Real Estate (VNQ)10.7%14.2%0.4713.5%
Bitcoin (BTCUSD)-33.0%43.7%-0.7913.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with QTRX
QTRX-43.8%83.8%-0.29-
Sector ETF (XLV)9.1%15.4%0.3931.8%
Equity (SPY)11.5%17.3%0.4938.6%
Gold (GLD)15.9%19.2%0.667.3%
Commodities (DBC)7.8%19.6%0.28-0.8%
Real Estate (VNQ)1.3%18.9%-0.0433.1%
Bitcoin (BTCUSD)2.2%51.6%0.2322.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with QTRX
QTRX-15.6%78.1%0.12-
Sector ETF (XLV)13.0%16.8%0.6432.8%
Equity (SPY)15.5%18.0%0.7337.8%
Gold (GLD)11.1%16.6%0.546.7%
Commodities (DBC)7.6%18.1%0.336.3%
Real Estate (VNQ)6.3%20.7%0.2631.0%
Bitcoin (BTCUSD)58.4%66.2%0.9815.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity4.6 Mil
Short Interest: % Change Since 10152026-2.5%
Average Daily Volume0.4 Mil
Days-to-Cover Short Interest10.7 days
Basic Shares Quantity47.4 Mil
Short % of Basic Shares9.6%

Earnings Returns History

Updated 11/12/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/9/202616.8%  
8/10/2026-40.0%-35.7%-32.3%
5/6/2026-16.4%-12.5%0.3%
3/2/2026-7.3%-19.4%-44.4%
1/8/202623.8%22.1%-5.2%
11/10/2025-2.3%8.0%47.5%
8/7/2025-13.8%-17.6%-18.0%
5/12/2025-19.0%-15.0%16.2%
...
SUMMARY STATS   
# Positive11911
# Negative192018
Median Positive12.7%16.8%16.2%
Median Negative-9.1%-12.8%-14.0%
Max Positive23.8%30.2%47.5%
Max Negative-54.8%-38.3%-44.4%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/9/202616.8%  
8/10/2026-40.0%-35.7%-32.3%
5/6/2026-16.4%-12.5%0.3%
3/2/2026-7.3%-19.4%-44.4%
1/8/202623.8%22.1%-5.2%
11/10/2025-2.3%8.0%47.5%
8/7/2025-13.8%-17.6%-18.0%
5/12/2025-19.0%-15.0%16.2%
3/17/2025-1.8%-1.2%-26.4%
1/14/2025-5.9%6.7%-14.3%
11/12/2024-18.3%-27.1%-26.4%
8/8/2024-14.8%-11.5%-6.5%
5/7/2024-4.9%-3.1%-10.0%
2/29/202412.7%17.1%-0.8%
1/11/2024-9.1%-16.1%-7.9%
11/6/20232.2%-6.2%5.2%
8/7/202316.9%16.8%21.5%
5/9/20230.6%4.1%31.9%
3/6/202312.1%-1.4%-7.9%
11/8/20221.3%30.2%40.5%
8/8/2022-54.8%-38.3%-42.6%
5/10/2022-9.1%-3.2%-1.5%
3/1/2022-6.3%-18.0%-13.6%
1/13/2022-0.4%-13.1%0.6%
11/4/20212.0%-2.5%-31.4%
8/5/2021-8.0%-12.6%-9.4%
5/5/2021-0.1%-10.6%2.5%
3/2/2021-15.1%-21.7%-24.2%
1/13/202113.8%28.3%35.4%
11/5/202012.7%10.6%7.3%
SUMMARY STATS   
# Positive11911
# Negative192018
Median Positive12.7%16.8%16.2%
Median Negative-9.1%-12.8%-14.0%
Max Positive23.8%30.2%47.5%
Max Negative-54.8%-38.3%-44.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/09/202610-Q
06/30/202608/10/202610-Q
03/31/202605/06/202610-Q
12/31/202503/02/202610-K
09/30/202511/10/202510-Q
06/30/202508/07/202510-Q
03/31/202505/12/202510-Q
12/31/202403/17/202510-K
09/30/202412/26/202410-Q
06/30/202408/08/202410-Q
03/31/202405/08/202410-Q
12/31/202302/29/202410-K
09/30/202311/08/202310-Q
06/30/202308/08/202310-Q
03/31/202305/09/202310-Q
12/31/202203/06/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/09/202610-Q
06/30/202608/10/202610-Q
03/31/202605/06/202610-Q
12/31/202503/02/202610-K
09/30/202511/10/202510-Q
06/30/202508/07/202510-Q
03/31/202505/12/202510-Q
12/31/202403/17/202510-K
09/30/202412/26/202410-Q
06/30/202408/08/202410-Q
03/31/202405/08/202410-Q
12/31/202302/29/202410-K
09/30/202311/08/202310-Q
06/30/202308/08/202310-Q
03/31/202305/09/202310-Q
12/31/202203/06/202310-K
09/30/202211/09/202210-Q
06/30/202208/08/202210-Q
03/31/202205/10/202210-Q
12/31/202103/01/202210-K
09/30/202111/04/202110-Q
06/30/202108/05/202110-Q
03/31/202105/06/202110-Q
12/31/202003/05/202110-K
09/30/202011/06/202010-Q
06/30/202008/05/202010-Q
03/31/202005/07/202010-Q
12/31/201903/13/202010-K

Recent Forward Guidance

Updated 11/10/2026

Latest: Q3 2026 Earnings Reported 11/9/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Cash BalanceReported 70.00 Mil -12.5% LoweredGuidance: 80.00 Mil for 2026
2026 RevenueReported142.00 Mil144.00 Mil146.00 Mil-0.7% LoweredGuidance: 145.00 Mil for 2026
2026 Adjusted Gross MarginReported48.0%49.0%50.0% 0.0%AffirmedGuidance: 49.0% for 2026


Prior: Q2 2026 Earnings Reported 8/10/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Year-end Cash BalanceReported 80.00 Mil -20.0% LoweredGuidance: 100.00 Mil for 2026
2026 RevenueReported142.00 Mil145.00 Mil148.00 Mil-15.5% LoweredGuidance: 171.50 Mil for 2026
2026 Non-GAAP Gross MarginReported48.0%49.0%50.0% -2.0%LoweredGuidance: 51.0% for 2026

Insider Activity

Updated 10/16/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Donnelly, William PSee FootnoteBuy81420262.9372,245211,678291,242Form
2Donnelly, William PSee footnoteBuy81420262.7527,15574,67674,676Form
3Meadows, BenjaminChief Commercial OfficerDirectBuy61220262.773,5009,6959,695Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Donnelly, William PSee FootnoteBuy81420262.9372,245211,678291,242Form
2Donnelly, William PSee footnoteBuy81420262.7527,15574,67674,676Form
3Meadows, BenjaminChief Commercial OfficerDirectBuy61220262.773,5009,6959,695Form
Core Cache Last Updated: 11/15/2026